deepull

An important moment for deepull today, as we announce the FDA granting Breakthrough Device Designation for our UllCORE Bloodstream Infection Test.   The one hour, direct-from-blood test detects 95% of sepsis-causing pathogens, as well as select genetic determinants of antimicrobial resistance.   We look forward to engaging in fruitful discussions with the FDA as we continue the development process. https://lnkd.in/dXqTaD3P   #deepull #FDA #diagnostics

🚀 Promising Advances in Bloodstream Infection Diagnostics at ID Week 🧬   deepull shared preliminary clinical data at ID Week showing 94% positive percent agreement with blood culture. The UllCORE BSI direct from blood test detected 60 of 64 pathogens found by blood culture. Additionally, we detected 23 pathogens missed by the initial blood culture but found in a subsequent blood culture or other culture. These data suggest that the UllCORE BSI test is shaping up to provide additional clinical value by besting blood culture's sensitivity and turnaround time.   #IDWeek #BloodstreamInfection #Diagnostics #UllCORE #HealthcareInnovation

MedTech Europe represents the medical technology industry across Europe, covering diagnostics, medical devices, and digital health. This membership marks an exciting step forward, and we couldn't be happier to join forces with MTE and the companies that they represent. Together, we’re looking forward to driving innovative research and further transforming diagnostics in healthcare. Find us: https://lnkd.in/g2Vjv3sG   Stay tuned for more updates as we embark on this exciting journey!   #Partnership #Research #Innovation #Collaboration

We’re delighted to announce the appointment of Didier Deltort to our Board of Directors.   Didier has a deep understanding of healthcare technologies, including diagnostics, having held senior leadership positions at GE Healthcare, Boston Scientific and Zimmer Biomet, amongst others.   Didier’s appointment comes at pivotal time for deepull, with clinical trials on the horizon for our innovative UllCORE diagnostic system, and we are looking forward to benefitting from his insights and expertise.   Please join us in welcoming Didier to our team!   Read the full announcement here: https://lnkd.in/ePRbwv9M   #Appointment #Biotech #Sepsis #Diagnostics

Thank you for joining us at our product unveiling during this year's ECCMID event. It was truly fantastic to see the enthusiasm and support from our community.   Stay connected with us by visiting our website for the latest updates: https://deepull.com/   Looking forward to keeping in touch and sharing more exciting news with you! #ECCMID #deepull #sepsis #diagnostic

We’re thrilled to announce the unveiling of our UllCORE diagnostic system at ESCMID 2024. This innovative system is set to revolutionize early sepsis detection by delivering 50 reportable results in just one hour, covering 95% of sepsis-causing pathogens and resistance genes.   Our real-time multiplex PCR test extracts total microbial DNA directly from 8 mL of whole blood, bypassing the lengthy blood culture process. This means faster, more accurate results that enable clinicians to make better decisions, reducing the risk of over- or under-treatment with antibiotics.   Read the full announcement here: https://lnkd.in/dWeqgdCZ Visit us https://deepull.com/ #deepull #UllCORE #sepsis #diagnostics #ESCMID2024

We are thrilled to be welcoming two new team members to deepull – Dr Kimberle Chapin as Chief Medical Officer and Wade Stevenson as Chief Marketing and Sales Officer.   Kimberle, Professor at the Warren Alpert School of Medicine at Brown University, has extensive experience in the diagnosis of infectious diseases, gained both in the clinic and the laboratory. This knowledge and hands-on experience will be instrumental in getting our automated sepsis diagnostic test to the patients who need it most.   Wade joins the team with over two decades of experience as a senior marketing leader, with a particular specialism in infectious diseases. His appointment will strengthen the commercial strategy for deepull’s direct-from-blood, rapid diagnostics system.     Read the full announcement here: https://lnkd.in/dAMwjD26 #Appointment #Biotech #Sepsis #Diagnostics